Results 331 to 340 of about 137,846 (394)

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang, Chao Yu, Mengyue Hu, Lu Wang, Meixia Chen, Hanmo Liu, Nan Wu, Jie Hou   +7 more
wiley   +1 more source

Oxidative stress induced liver damage in dengue is exacerbated in those with obesity

Kuruppu H, Karunananda M, Jeewandara C, Gomes L, Dissanayake D, Ranatunga C, Chathurangika PH, Senatilleke N, Warnakulasuriya N, Wickramanayake RH, Wijewickrama A, Idampitiya D, Ogg GS, Malavige GN.   +13 more
europepmc   +1 more source

Advances in biosynthesis of chiral amide herbicides and the key enzymes: dimethenamid-P and S-metolachlor as case studies. [PDF]

Bioresour Bioprocess
Cheng F, Zhou YL, Yang DC, Zhao DY, Xue YP, Zheng YG.   +5 more
europepmc   +1 more source

Paracetamol and its metabolites in children and adults with spinal muscular atrophy – a population pharmacokinetic model

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of the study was to investigate whether differences in paracetamol pharmacokinetics (PK) between spinal muscular atrophy (SMA) patients and healthy controls (HC) could be attributed to specific clinical covariates. Methods Nonlinear mixed‐effects modelling (NONMEM 7.4) was used to develop a population PK model, explore covariates ...
Qiaolin Zhao, Marie Mostue Naume, Brenda C. M. de Winter, Thomas Krag, Sissel Sundell Haslund‐Krog, Karoline Lolk Revsbech, John Vissing, Helle Holst, Morten Hylander Møller, Tessa Munkeboe Hornsyld, Morten Dunø, Christina Engel Hoei‐Hansen, Alfred Peter Born, Per Bo Jensen, Mette Cathrine Ørngreen   +14 more
wiley   +1 more source

Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus. [PDF]

Sci Rep
Morath B, Klein S, Chiriac U, Müller Y, Koeppel L, Frey O, Lanzinger H, Schlegel P, Hamed S, Nurjadi D, Ehlermann P, Karck M, Meyer AL.   +12 more
europepmc   +1 more source

Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Prednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE ...
Naïm Bouazza, Michaela Semeraro, Gabrielle Lui, Léo Froelicher‐Bournaud, Laure Choupeaux, Jean‐Marc Treluyer, Sihem Benaboud, Joelle Terzic, Eric Hachulla, Philippe Remy, Jérôme Harambat, Alexandre Karras, Caroline Rousset‐Rouviere, Anne Jolivot, Zahir Amoura, Eric Daugas, Aurélie Hummel, Rémi Salomon, Jean‐Christophe Lega, Stéphane Decramer, Alexandre Belot, Delphine Gobert, Nathalie Costedoat‐Chalumeau, Stanislas Faguer, Isabelle Melki, Noémie Jourde‐Chiche, Brigitte Bader‐Meunier   +26 more
wiley   +1 more source

Non-invasive liver disease assessments: can they replace liver biopsy? [PDF]

Hepatobiliary Surg Nutr
Milani I, Leonetti F, Capoccia D.
europepmc   +1 more source

Serum transaminases in the newborn.

Indian pediatrics, 1990
L, RAMAKUMAR, K N, DOGRA, S C, SOOD
openaire   +2 more sources

Real‐world population pharmacokinetics of tezacaftor‐ivacaftor in children with cystic fibrosis: The SYM‐CF study

British Journal of Clinical Pharmacology, EarlyView.
Aims The clinical effectiveness of tezacaftor‐ivacaftor in children with cystic fibrosis (cwCF) varies; some patients respond while others do not or have adverse effects. The pharmacokinetics (PK) of tezacaftor‐ivacaftor are inadequately published, especially in children.
Steffie E. M. Vonk, Suzanne W. J. Terheggen‐Lagro, Eric G. Haarman, Hettie M. Janssens, Anke‐Hilse Maitland–van der Zee, E. Marleen Kemper, Ron A. A. Mathôt, on behalf of the Amsterdam Mucociliary Clearance Disease (AMCD) research group   +7 more
wiley   +1 more source